Napredna pretraga

Pregled bibliografske jedinice broj: 731305

Lysosomal acid lipase deficiency : an under- recognized cause of dyslipidaemia and liver dysfunction.


Reiner, Željko; Guardamagna, O.; Nair, D.; Soran, H.; Hovingh, K.; ...; Ćorić, Marijana; ...; Ros, E.
Lysosomal acid lipase deficiency : an under- recognized cause of dyslipidaemia and liver dysfunction. // Atherosclerosis (Amsterdam), 235 (2014), 1; 21-30 doi:10.1016/j.atherosclerosis.2014.04.003 (međunarodna recenzija, članak, znanstveni)


Naslov
Lysosomal acid lipase deficiency : an under- recognized cause of dyslipidaemia and liver dysfunction.

Autori
Reiner, Željko ; Guardamagna, O. ; Nair, D. ; Soran, H. ; Hovingh, K. ; ... ; Ćorić, Marijana ; ... ; Ros, E.

Izvornik
Atherosclerosis (Amsterdam) (0021-9150) 235 (2014), 1; 21-30

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Cholesteryl ester storage disease; Dyslipidaemia; Hepatomegaly; Lysosomal acid lipase deficiency; Wolman disease

Sažetak
Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive lysosomal storage disease caused by deleterious mutations in the LIPA gene. The age at onset and rate of progression vary greatly and this may relate to the nature of the underlying mutations. Patients presenting in infancy have the most rapidly progressive disease, developing signs and symptoms in the first weeks of life and rarely surviving beyond 6 months of age. Children and adults typically present with some combination of dyslipidaemia, hepatomegaly, elevated transaminases, and microvesicular hepatosteatosis on biopsy. Liver damage with progression to fibrosis, cirrhosis and liver failure occurs in a large proportion of patients. Elevated low-density lipoprotein cholesterol levels and decreased high-density lipoprotein cholesterol levels are common features, and cardiovascular disease may manifest as early as childhood. Given that these clinical manifestations are shared with other cardiovascular, liver and metabolic diseases, it is not surprising that LAL-D is under-recognized in clinical practice. This article provides practical guidance to lipidologists, endocrinologists, cardiologists and hepatologists on how to recognize individuals with this life- limiting disease. A diagnostic algorithm is proposed with a view to achieving definitive diagnosis using a recently developed blood test for lysosomal acid lipase. Finally, current management options are reviewed in light of the ongoing development of enzyme replacement therapy with sebelipase alfa (Synageva BioPharma Corp., Lexington, MA, USA), a recombinant human lysosomal acid lipase enzyme.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekt / tema
108-0532264-0048 - Hepatocelularni tumori (Marijana Ćorić, )
108-1080134-0121 - Percepcija i prevencija čimbenika rizika za aterosklerozu u Hrvatskoj (Željko Reiner, )

Ustanove
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati